Last reviewed · How we verify
NCT06789510
Treatment of Peyronie's Disease With Platelet-Rich Plasma
NA trial testing Autologous Platelet Rich Plasma in Peyronies Disease in 10 participants. Participants enrolled and being followed up; not accepting new ones.
1 October 2025
Quick facts
| Lead sponsor | Herlev Hospital |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 10 March 2025 |
| Primary completion | 1 October 2025 |
| Estimated completion | 1 January 2026 |
| Sites | 1 location across Denmark |
Drugs / interventions tested
- Autologous Platelet Rich Plasma — full drug profile →
- Saline solution
Conditions studied
- Peyronies Disease — all drugs for Peyronies Disease →
Sponsor
Herlev Hospital
Who can join
18 and older, male only, with Peyronies Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this pilot study is to optimize a planned randomized, double-blind, placebo-controlled clinical trial evaluating the effects of Platelet-Rich Plasma (PRP) intralesional injections in men affected by Peyronie's disease (PD) in the fibrotic phase. The pilot study aims to identify potential challenges in the practical execution of the clinical trial, particularly regarding PRP preparation and the blinding process. Furthermore, it seeks to evaluate the effects of PRP injections.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06789510
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Autologous Platelet Rich Plasma
Trials testing the same drug.
- NCT07117955 — Platelet-Rich Plasma for Peyronie's Disease · NA · recruiting
- NCT07005661 — Use of PRP in Open Surgery for Type A Aortic Dissection · Phase 2, PHASE3 · not yet recruiting
- NCT04350125 — PRP for the Treatment of Erectile Dysfunction (ED) · Phase 1 · completed
- NCT04512287 — PRP for Treatment of Peyronie's Disease · Phase 2 · completed
- NCT04396795 — Safety and Efficacy of Autologous Platelet-Rich Plasma for Erectile Dysfunction. · Phase 2 · completed
Other recruiting trials for Peyronies Disease
Currently open trials in the same condition.
- NCT07177833 — Title Fractioned CO2 Laser in the Treatment of Chronic Phase Peyronie's Disease · Phase 1 · recruiting
- NCT07117955 — Platelet-Rich Plasma for Peyronie's Disease · NA · recruiting
Other Herlev Hospital trials
Trials by the same sponsor.
- NCT07367412 — Zinc Supplementation and Infections in Older Medical Patients · NA · not yet recruiting
- NCT07171216 — The Effect of REgulation of PArathyroId hoRmone in Patients With Chronic Kidney Disease to Investigate the Change in Bon · NA · recruiting
- NCT07272187 — Endoscopic Ultrasound-guided Radiofrequency Ablation for Upper Gastrointestinal Tract Lesions · recruiting
- NCT07117955 — Platelet-Rich Plasma for Peyronie's Disease · NA · recruiting
- NCT07144046 — Tape Application Protocol for Enhanced Scars · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06789510 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Herlev Hospital
- Last refreshed: 13 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06789510.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing